Background Pulmonary hypertension results in increased morbidity and mortality in children after surgical repair of congenital heart defects. Various vasodilators have been unsuccessful in providing preferential pulmonary vasodilation in these patients. Identification of a more preferential pulmonary vasodilator would improve the assessment, management, and outcome of these children. To determine whether ATP-MgCl2 is a preferential pulmonary vasodilator in children with pulmonary hypertension secondary to congenital heart defects, ATP-MgCl2 was administered during routine cardiac catheterization, and the effects were compared with tolazoline. In addition, ATP-MgCl2 was infused intravenously during episodes of postoperative pulmonary hypertension.
Use of ATP-MgCl2 in the Evaluation
Background Pulmonary hypertension results in increased morbidity and mortality in children after surgical repair of congenital heart defects. Various vasodilators have been unsuccessful in providing preferential pulmonary vasodilation in these patients. Identification of a more preferential pulmonary vasodilator would improve the assessment, management, and outcome of these children. To determine whether ATP-MgCl2 is a preferential pulmonary vasodilator in children with pulmonary hypertension secondary to congenital heart defects, ATP-MgCl2 was administered during routine cardiac catheterization, and the effects were compared with tolazoline. In addition, ATP-MgCl2 was infused intravenously during episodes of postoperative pulmonary hypertension.
Methods and Results During cardiac catheterization in 28 children, the effect of ATP-MgCl2 on the pulmonary artery pressure (PAP) and pulmonary vascular resistance index (Rp) was compared with tolazoline. ATP-MgCl2 (0.1 mg of ATP per P ulmonary hypertension is a serious problem in children with congenital heart defects associated with increased pulmonary blood flow (particularly when associated with hypoxemia) or left ventricular inflow obstruction. Increased pulmonary arterial smooth muscle increases pulmonary vascular resistance and the risk for postoperative pulmonary hypertensive crises. Long-term elevation of pulmonary arterial pressure causes intimal hyperplasia and microvascular obstruction,' leading to irreversible pulmonary vascular disease and Eisenmenger's syndrome.2 During cardiac catheterization, the measurement of pulmonary vascular resistance and the assessment of pulmonary vasoreactivity to vasodilators compare favorably with lung biopsy findings3 and therefore are used to determine which patients may have developed permanent vascular changes. Whether response to pulmonary vasodilators can predict which patients will have immediate postoperative hypertension or hypertensive crises is unclear.
Many vasodilators, including oxygen, prostacyclin,4 prostaglandin E1,5 and tolazoline,67 have been used in children with pulmonary hypertension secondary to congenital heart defects for both evaluation of pulmonary vasoreactivity and treatment of postoperative pulmonary hypertension. However, all of these may produce side effects. ATP is an endothelium-dependent vasodilator8 whose rapid metabolism and short duration of action make it a preferential dilator for the pulmonary circulation when infused intravenously or directly into the pulmonary artery.9 Therefore, to determine whether ATP-MgCl2 is a safe, effective, and preferential pulmonary vasodilator in children with pulmonary hypertension secondary to congenital heart defects, two studies were performed. In one study, ATP-MgCl2 was administered to 28 children during routine diagnostic cardiac catheterization to assess pulmonary vasoreactivity, and the effects were compared with those of tolazoline. In the second study, ATP-MgCl2 was administered to 7 children with pulmonary hypertension immediately after surgical repair of congenital heart defects to determine whether ATP-MgCl2 lowers pulmonary arterial pressure and prevents pulmonary hypertensive crises Protocol Baseline (preinfusion) measurements of right atrial and pulmonary and systemic arterial pressures (hemodynamic variables) were made. Systemic arterial blood gases and pH were also measured. ATP-MgGl2 (0.01 mg of ATP per kilogram per minute) was infused into the main pulmonary artery. The hemodynamic variables and systemic arterial blood gases and pH were measured after 15 minutes. If there was no decrease in mean systemic arterial pressure or worsening of the systemic arterial blood gases, the dose of ATP-MgGl2 was sequentially increased (0.025, 0.05, 0.10, and 0.2 mg of ATP per kilogram per minute). An improvement in the patient's condition was assessed by a decrease in mean pulmonary arterial pressure without a proportional decrease in mean systemic arterial pressure, by a decrease in the number of pulmonary hypertensive crises per hour (defined as an acute increase in pulmonary arterial pressure associated with a decrease in systemic arterial pressure and/or a decrease in oxygenation), or by an improvement in systemic arterial blood gases at constant ventilation. The dose of ATP-MgGl2 was adjusted to produce maximal pulmonary vasodilation and minimal systemic vasodilation (optimal dose). If improvement occurred, the optimal dose was maintained for 12 to 24 hours and then gradually reduced and discontinued. If there was a 20% decrease in systemic arterial pressure, the infusion was reduced; if there was no improvement at the maximum dose, the infusion was stopped.
Drug Preparation
ATP and MgGl2 (Sigma Chemical Co) were prepared as sterile solutions of 100 and 33 mg/mL, respectively, in sterile water; 1 mol/L NaOH was added to the solutions to obtain pH 7.2 to 7.4. The solutions were sterilized by filtration using a 0.22-,um filter. The sterilized solutions were then placed into 10-mL vials. Each lot was tested for particulate matter, bacteria, and pyrogens. The vials were frozen and stored at 20°C. The stability of ATP was set at 60 days.11
To infuse ATP-MgGl2, the contents of both vials were thawed immediately before use and combined to yield a ratio of 1: 0.33 by weight (ATP: MgGl2). The resulting solution was mixed with sterile water for injection. The final concentration of ATP-MgGl2 was determined by the patient's weight, so that an infusion rate of 2 mL/h corresponded to a concentration of 0.05 mg of ATP per kilogram per minute.
Tolazoline (25 mg/mL) (CIBA-GEIGY) was diluted in 3 mL of sterile 5% dextrose in 0.2% saline for infusion.
Measurements
During study 1, right atrial, pulmonary arterial, and pulmonary capillary wedge pressures were measured using an endhole balloon catheter (Arrow Intl) connected via a fluid-filled system to a pressure transducer (Abbott Labs). Mean pressure was obtained by electrical integration. Systemic arterial pressure was measured either by a catheter placed in the ascending or descending aorta or by an automated sphygmomanometer (Critikon Inc). Heart rate was measured with a cardiotachometer. During study 2, pulmonary and systemic arterial and right atrial pressures were measured using indwelling catheters placed during surgery.
Systemic arterial blood gases and pH were measured using a 178 pH/Blood Gas Analyzer (Ciba-Corning Diagnostic). Hemoglobin and hemoglobin oxygen saturation were measured in heparinized whole blood using an OSM2 oximeter (Radiometer America Inc). In some patients, systemic arterial hemoglobin oxygen saturation was measured using pulse oximetry (Nellcor Inc). During cardiac catheterization, oxygen consumption was measured using a custom-made, flow-by system. 10 Pulmonary and systemic blood flows and vascular resistances were estimated using standard formulas with oxygen consumption in the baseline state.
Data Analysis
The mean±SD values were calculated for the hemodynamic variables, pulmonary and systemic blood flows, and vascular resistances during baseline and in each experimental condition. For study 1, comparisons between baseline and each dose of ATP-MgCl2 and tolazoline for these variables were made by ANOVA for repeated measures with multiple-comparison testing. For study 2, comparisons between baseline and the maximum response to ATP-MgCl2 for these variables were made by the paired t test. P<.05 was considered statistically significant.
Results

Study 1 -ATP-MgCl During Cardiac Catheterization
The baseline mean pulmonary arterial pressure was 54.3±11.9 mm Hg, which was 84% of mean systemic arterial pressure ( ATP-MgCl2 was infused for 30 minutes to 30 hours (median, 6 hours). There were no serious complications. Four patients survived surgery and were discharged from the hospital; 3 patients (patients B, E, and G) died.
Discussion
The present study shows that ATP-MgCl2 is a safe and effective vasodilator whose short half-life provides preferential pulmonary vasodilation in children with pulmonary hypertension secondary to congenital heart defects. During cardiac catheterization, intrapulmonary infusions of ATP-MgCl2 decreased pulmonary arterial pressure and pulmonary vascular resistance and increased pulmonary blood flow. ATP-MgCl2 produced pulmonary vasodilation comparable to tolazoline without producing tachycardia, nausea, or vomiting. After cardiac surgery, ATP-MgCl2 decreased pulmonary arterial pressure and the number of postoperative pulmonary hypertensive crises.
The vasodilating effects of ATP and its rapid metabolism have been known for more than 30 years.12 ATP binds to P2 receptors on vascular endothelial cells,13 increasing the formation of nitric oxide and resulting in an increased smooth muscle cell concentration of cyclic GMP, the intracellular messenger involved in smooth muscle relaxation.812 Metabolism of extracellular ATP occurs rapidly by endothelial cell ATPases, resulting in a half-life of <6 seconds.14 In fact, ATP is almost completely cleared after a single passage through the lung.
ATP-MgCl2 also has been studied during pulmonary hypertension in animals. We have investigated the effects of infusions of ATP-MgCl2 on the circulation in newborn lambs at rest and during pulmonary hypertension induced by either the infusion of U46619, a thromboxane A2 mimetic, or hypoxia. ASD indicates atrial septal defect; coarct, aortic coarctation; sip, after surgery; VSD, ventricular septal defect; TOF, tetralogy of Fallot; shunt, postoperative aortopulmonary shunt; DS, Down's syndrome; DORV, double-outlet right ventricle; PDA, patent ductus arteriosus; AVS, atrioventricular septal defect; LTGA, L-transposition of the great arteries; a, unable to calculate due to differential pulmonary blood flow; DILV, double-inlet left ventricle; PAB, postoperative pulmonary artery band; and n, dose not given; n=28.
Median patient age was 6 mo.
by endothelial-derived nitric oxide rather than by prostacyclin or adenosine. ATP-MgCl2 is a potent vasodilator whose rapid metabolism allows for preferential vasodilation of the vascular bed (pulmonary or systemic) first encountered. These properties make ATP- advanced pulmonary hypertension who would not be identified by tolazoline. As such it may be a better predictor of pulmonary vasoreactivity and may identify those patients most at risk of postoperative pulmonary hypertensive crises. Further studies will need to be performed to determine this.
Unlike the study of tients in that study had pulmonary hypertension secondary to parenchymal lung disease without an intracardiac shunt. Administration of ATP decreased pulmonary artery pressure and vascular resistance and simultaneously decreased arterial oxygenation. After discontinuation, pulmonary artery pressure and vascular resistance rose to levels higher than preinfusion levels. In these patients, vasodilation with ATP may have im- ATP-MgCl2 produced preferential pulmonary vasodilation in patients after cardiac surgery, even though cardiopulmonary bypass causes endothelial dysfunction.20 24 The 2 patients who did not have a preferential pulmonary vasodilating response to ATP-MgCl2 were older and may have had more endothelial cell dysfunction. More studies will need to be performed to determine if infusion of ATP-MgCl2 decreases mortality or shortens postoperative course in these patients.
Conclusions
The present study shows that ATP-MgCl2 is a safe and effective vasodilator whose short half-life provides preferential pulmonary vasodilation in children with pulmonary hypertension secondary to congenital heart defects, producing maximal pulmonary vasodilation without systemic effects. In addition, it has no significant side effects. ATP-MgCl2 also lowers pulmonary arterial pressure and decreases the number of pulmonary hypertensive crises in the immediate postoperative period. Therefore, we suggest that ATP-MgCl2 be considered as an alternative to other vasodilators in the assessment of children with pulmonary hypertension during cardiac catheterization. We also suggest that ATP-MgCl2 be considered in the treatment of postoperative pulmonary hypertension or life-threatening pulmonary hypertensive crises.
